abstract |
M-CSF muteins are provided, along with pharmaceutical compositions containing a M-CSF mutein, kits containing a pharmaceutical composition, methods of preventing and treating bone metastases in a subject afflicted with metastatic cancer, and methods of screening for M-CSF muteins. |